IRIS
MENNINI, FRANCESCO SAVERIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.398
EU - Europa 4.671
AS - Asia 4.004
SA - Sud America 697
Continente sconosciuto - Info sul continente non disponibili 474
AF - Africa 73
OC - Oceania 7
Totale 39.324
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.225
SG - Singapore 1.899
IT - Italia 1.867
CN - Cina 677
BR - Brasile 563
RU - Federazione Russa 497
IE - Irlanda 463
DE - Germania 401
VN - Vietnam 338
HK - Hong Kong 311
UA - Ucraina 310
FR - Francia 257
GB - Regno Unito 221
FI - Finlandia 184
SE - Svezia 138
BD - Bangladesh 132
JP - Giappone 102
ID - Indonesia 101
CA - Canada 99
KR - Corea 96
NL - Olanda 95
IN - India 85
PL - Polonia 48
AR - Argentina 42
IQ - Iraq 37
ES - Italia 33
IR - Iran 31
BE - Belgio 30
ZA - Sudafrica 30
AT - Austria 29
CH - Svizzera 27
MX - Messico 26
EC - Ecuador 24
PH - Filippine 21
TW - Taiwan 21
TR - Turchia 20
CO - Colombia 19
CL - Cile 18
AE - Emirati Arabi Uniti 17
PK - Pakistan 17
MY - Malesia 15
SA - Arabia Saudita 15
JM - Giamaica 13
JO - Giordania 10
EU - Europa 9
RO - Romania 9
UZ - Uzbekistan 9
PT - Portogallo 8
UY - Uruguay 8
EG - Egitto 7
IL - Israele 7
VE - Venezuela 7
AU - Australia 6
CZ - Repubblica Ceca 6
MA - Marocco 6
PY - Paraguay 6
AL - Albania 5
BH - Bahrain 5
BO - Bolivia 5
CR - Costa Rica 5
DK - Danimarca 5
DZ - Algeria 5
GR - Grecia 5
HN - Honduras 5
LT - Lituania 5
NP - Nepal 5
SV - El Salvador 5
TH - Thailandia 5
BG - Bulgaria 4
HR - Croazia 4
KE - Kenya 4
OM - Oman 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
DM - Dominica 3
GH - Ghana 3
HU - Ungheria 3
KG - Kirghizistan 3
KZ - Kazakistan 3
MN - Mongolia 3
NO - Norvegia 3
RS - Serbia 3
AO - Angola 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GT - Guatemala 2
GY - Guiana 2
HT - Haiti 2
LB - Libano 2
MK - Macedonia 2
PE - Perù 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TN - Tunisia 2
ZM - Zambia 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
Totale 38.833
Salva come PNG Salva come JPEG
Città #
Wilmington 7.138
Houston 6.895
Woodbridge 6.755
Singapore 1.010
Fairfield 906
Ashburn 648
San Jose 567
Chandler 498
Ann Arbor 426
Council Bluffs 400
Dublin 386
Rome 349
Seattle 345
Hong Kong 305
Cambridge 296
Medford 293
New York 283
Beijing 261
Jacksonville 259
Milan 219
Santa Clara 202
Dearborn 182
Los Angeles 165
The Dalles 156
Lawrence 136
Helsinki 120
Lauterbourg 106
Dong Ket 94
Tokyo 93
Moscow 91
San Diego 88
Buffalo 77
Jakarta 77
Dallas 73
Ho Chi Minh City 71
Hanoi 67
North Bergen 65
Menlo Park 58
Phoenix 53
São Paulo 50
Chicago 43
London 39
Nuremberg 39
Toronto 35
Florence 32
Orem 31
Naples 30
Catania 29
Verona 29
Redwood City 28
Turin 28
Boardman 25
Mülheim 25
Seoul 25
Warsaw 25
Amsterdam 24
Bologna 24
Chennai 24
Springfield 24
Brussels 23
Nanjing 23
Atlanta 21
Denver 20
Frankfurt am Main 20
Munich 20
Belo Horizonte 19
Da Nang 18
Norwalk 18
San Francisco 18
Miami 17
Redondo Beach 17
Guangzhou 16
Hangzhou 16
Johannesburg 16
Napoli 16
Parma 16
Rio de Janeiro 16
Palermo 15
Paris 15
Shanghai 15
Montreal 14
Taipei 14
Washington 14
Brooklyn 13
Manchester 13
Messina 13
Zurich 13
Creede 12
Curitiba 12
Falls Church 12
Haiphong 12
Kraków 12
Lexington 12
Madrid 12
Ottawa 12
Perugia 12
Philadelphia 12
Bari 11
Brasília 11
Columbus 11
Totale 31.444
Salva come PNG Salva come JPEG
Nome #
Strategie e performance nel mercato farmaceutico italiano: un'analisi empirica 574
Extending influenza vaccination to individuals aged 50-64: a budget impact analysis 539
A one-year prospective costing study of botulinum toxin type A treatment of chronic tension headache 479
A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache 475
Economic Burden of Human Papillomavirus-Related Diseases in Italy 473
General disease costing principles 467
Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline 467
Governance of preventive health intervention and on time verification of its efficiency: the GIOVE study 461
The perception of corruption in health: AutoCM methods for an international comparison 459
Economic effects of treatment of chronic kidney disease with low-protein diet 453
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. 452
Scenari e strategie nel settore farmaceutico 448
Cost of poor adherence to anti-hypertensive therapy in five European countries 447
Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 446
Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group 443
Towards the eradication of HPV infection through universal specific vaccination 432
Hospital costs incurred by the Italian national health service for invasive cervical cancer 431
Health and economic impact associated with a quadrivalent HPV vaccine in Italy 430
Cost-effectiveness analysis for the treatment of chronic kidney disease with low-protein diet 429
Rapid responses to: Letter to the Editor, by L. Garattini and G. Casadei [Vaccine 27 (38) (20 August 2009) 5171] 428
A One-Year Economic Evaluation of Botulinum Toxin Type A Treatment of Chronic Tension-type Headaches: Part II 423
The new perspectives of italian national health service 419
Rapporto CEIS-Sanità 2003: bisogni, risorse e nuove strategie 418
Rapporto CEIS-Sanità 2005: sette parole chiave del SSN 415
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 414
Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study 411
The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. 411
Improving care through health economics analyses: cost of illness and headache 409
Public health value of universal HPV vaccination 407
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 404
Rapporto CEIS-Sanità 2007: responsabilità, autonomia, sussidiarietà, integrazione, valutazione, empowerment: 6 "nuove" parole chiave per il futuro del SSN 403
Oral vs injection therapy in the treatment of metastatic colorectal cancer. a cost minimization analysis in a public hospital of the lazio region [Terapia orale vs terapia infusionale nel trattamento del cancro del colon retto localmente avanzato o avanzato analisi di minimizzazione dei costi presso una struttura ospedaliera della regione lazio] 403
Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study. [Costi diretti e indiretti associati a malattie allergiche respiratorie in Italia. Uno studio probabilistico di cost of illness] 402
Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis 402
Criteri per l'allocazione regionale delle risorse per la sanità: riflessioni sul caso italiano 398
The Welfare States in a United Europe 397
Rapporto CEIS-Sanità 2004: sostenibilità, equità e ricerca dell'efficienza 397
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy 397
Anti-HPV vaccination in Italy: a review of recent economic data for Italy 396
Pilot evaluation of indirect costs and the impact of bipolar disorder type I 396
Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study 386
Equità e fairness del servizio sanitario nazionale italiano 383
Economic evaluation of spondyloarthritis: Economic impact of diagnostic delay in Italy 383
Joint Procurement and the EU perspective. In Law and Economics of Public Procurement reforms 382
Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region 381
Dinamiche e determinanti del settore farmaceutico in Europa 378
Does regional belonging explain the similarities in the expenditure determinants of Italian healthcare deliveries?: An approach based on Artificial Neural Networks 377
Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study 374
Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients 369
PDB51. Direct and indirect cost of diabetes in italy: A prevalence probabilistic approach 368
Primary Biliary Cholangitis: advances in management and treatment of the disease 367
Human papillomavirus 9-valent vaccine for cancer prevention: A systematic review of the available evidence 366
Improving care through health economics analyses: cost of illness and headache (general disease costing principles) 360
The economic burden of musculoskeletal disorders on the Italian social security pension system estimated by a Monte Carlo simulation 354
The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports. 354
Time trade-off procedure for measuring health utilities loss with human papillomavirus–induced diseases: a multicenter, retrospective, observational pilot study in Italy 354
Il settore industriale sanitario in Italia 350
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study 348
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada 345
A novel method to value real options in health care: The case of a multicohort human papillomavirus vaccination strategy 337
Dimensioni e tendenze del mercato farmaceutico in Italia (1980/1997) 335
Analisi di impatto di budget di pasireotide in pazienti con Acromegalia nella prospettiva del Servizio Sanitario Nazionale 327
Fraud and Corruption in Healthcare: Recognizing Such Phenomena to Combat Them. 325
Il settore industriale farmaceutico italiano 320
Strategie e performance delle grandi aziende farmaceutiche in Italia (1979-2001) 318
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 316
Health policy model: Long-term Predictive results associated with the management of hepatitis C virus-induced diseases in Italy 315
Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanerceptt 308
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy 308
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 307
Economic burden of HPV9-related diseases: a real-world cost analysis from Italy 306
Early treatment in HIV patients: a cost–utility analysis from the Italian perspective 297
Introduzione 292
Economics of Headache 287
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy 286
Erratum to: Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 266
Invecchiamento della popolazione e sostenibilità del SSN:il ruolo della Health Technology Assessment (HTA) per la valutazione tecnica, economica ed organizzativa della Sanità del futuro 264
null 263
The economic impact of biosimilars in Italy: a scenario analysis 255
Screening strategies for Hepatitis C Virus elimination in Italy 252
Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma 248
Using real-world data to estimate the Social Security Costs of Retinal Diseases: Results from the Observatory on Legal Blindness 248
Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of 3 European Countries 247
HPV Vaccination Concepts in the Reality of Today 244
Budget Impact Analysis della gestione dell'agitazione psicomotoria con loxapina inalatoria in Italia. 243
La corruzione in sanità: i nuovi strumenti per individuarla e contrastarla 242
Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer 237
Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. Human menopausal gonadotropin for women undergoing IVF 236
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries 214
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 213
Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto 213
Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy 212
Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group 203
Artificial Urinary Sphincters as a Treatment for Post-Prostatectomy Severe Urinary Incontinence in Italy: A Cost-Utility Analysis 197
Economic Consequences of Anti-HCV Antiviral Treatment Investment from the NHS Perspective 196
Estimation of the number of HCV-positive patients in Italy 180
Burden economico della neuropatia ottica ereditaria di Leber (LHON) in Italia: stima dei costi indiretti e diretti a carico del paziente. 179
The burden of atopic dermatitis in adults in Italy 178
PIN79 - ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE: A REAL-WORLD-BASED ANALYSIS FROM PITER DATA 175
Ipercolesterolemia e rischio cardiovascolare in Italia: modello di cost of illness. 175
Totale 34.898
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.720
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.720
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.388 0 0 139 88 71 87 148 143 94 82 147 389
2022/20231.701 176 111 51 198 148 403 163 104 142 33 118 54
2023/2024946 87 44 66 31 79 226 66 50 61 52 45 139
2024/20253.424 117 831 348 228 106 265 214 172 308 394 205 236
2025/20265.313 335 164 534 349 436 293 749 650 716 519 308 260
2026/2027652 270 309 73 0 0 0 0 0 0 0 0 0
Totale 39.324